MARK2

Across TCGA pan-cancer cohorts, MARK2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MARK2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MARK2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MARK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where MARK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.901	.005	40	view →
CCRCC	OS	Median	II,III,IV	0.860	0.615	.010	8	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.840	.010	6	view →
HNSC	DFS	Tertile	II,III,IV	0.974	0.864	.038	3	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MARK2–UCEC (OS)

Open the UCEC breakdown →